1 / 7

Momelotinib（CYT-387）1056634-68-4 | EOS Med Chem

Momelotinib (CYT-387) 1056634-68-4 is an inhibitor of Janus kinases JAK1 and JAK2 and acting as an ATP competitor with IC50 values of 11 and 18nM, separately.In 2016, Momelotinib is being developed as a drug fro myelofibrosis and currently undertake phase I/II clinical trials.Additional possible treatment myelofibrosis includes other myeloproliferative neoplasms, cancer and inflammatory conditions. For more details visit are website http://www.eosmedchem.com/1056634-68-4.html<br>

eosmedchem
Télécharger la présentation

Momelotinib（CYT-387）1056634-68-4 | EOS Med Chem

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Momelotinib（CYT-387）1056634-68-4 | EOS Med Chem

  2. ABOUT US EOS Med Chem is the largest chemistry products and services provider based in China. Its centre organizations include an index of unusually created frameworks and building blocks; custom amalgamation; prepare advancement; and assembling of key intermediates. EOS Med Chem has the partnership with top 20 pharmaceutical companies and always receives positive feedback by all of them. EOS Med Chem likewise gives high calibre and financially savvy custom synthesis service. For more info visit http://www.eosmedchem.com/

  3. ABOUT Momelotinib（CYT-387 Momelotinib (CYT-387) 1056634-68-4 is an inhibitor of Janus kinases JAK1 and JAK2 and acting as an ATP competitor with IC50 values of 11 and 18nM, separately.In 2016, Momelotinib is being developed as a drug fro myelofibrosis and currently undertake phase I/II clinical trials.Additional possible treatment myelofibrosis includes other myeloproliferative neoplasms, cancer and inflammatory conditions. For more details visit are website http://www.eosmedchem.com/1056634-68-4.html

  4. Momelotinib（CYT-387）1056634-68-4 | EOS Med Chem

  5. Basic Details Of Momelotinib（CYT-387）1056634-68-4 CAS NO. - 1056634-68-4 Formula - C23H22N6O2 Weight - 414.45978

  6. Contact Us EOS Med Chem, Medicinal Chemical manufacturer and Services Provider TEL: 0086-531-69905422 EMAIL: info@eosmedchem.com ; eosmedchem@gmail.com WEB: www.eosmedchem.com Technical Support:chem960 ADD : 1811 Room,Yangguangxinroad,Jinancity,china

More Related